data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Atossa Therapeutics
(NASDAQ:ATOS)
$1.01
00
At close: Jul 1
$1.00
-0.0100[-0.99%]
PreMarket: 7:36PM EDT
Day High/Low- - -
52 Week High/Low0.84 - 7.15
Open / Close- / -
Float / Outstanding126.6M / 126.6M
Vol / Avg.- / 1.8M
Mkt Cap127.9M
P/E-
50d Avg. Price1.02
Div / Yield-
Payout Ratio-
EPS-0.04
Total Float126.6M

Atossa Therapeutics (NASDAQ:ATOS), Quotes and News Summary

Atossa Therapeutics (NASDAQ: ATOS)

Day High/Low- - -
52 Week High/Low0.84 - 7.15
Open / Close- / -
Float / Outstanding126.6M / 126.6M
Vol / Avg.- / 1.8M
Mkt Cap127.9M
P/E-
50d Avg. Price1.02
Div / Yield-
Payout Ratio-
EPS-0.04
Total Float126.6M
Benzinga - 3 days ago
Benzinga - 3 days ago
Benzinga - May 9, 2022, 5:06PM
Benzinga - Apr 20, 2022, 9:30AM
Benzinga - Mar 8, 2022, 9:16AM
Benzinga - Feb 28, 2022, 4:56PM
Benzinga - Jan 18, 2022, 9:31AM
Benzinga - Dec 22, 2021, 9:31AM
Benzinga - Dec 6, 2021, 9:17AM
Benzinga - Sep 30, 2021, 9:34AM
Benzinga - Sep 17, 2021, 3:37PM
Benzinga - Sep 15, 2021, 9:45AM
Benzinga - Sep 10, 2021, 1:50PM
Benzinga - Sep 10, 2021, 10:46AM
Benzinga - Sep 7, 2021, 5:27PM
Benzinga - Sep 2, 2021, 11:00AM
Benzinga - Sep 2, 2021, 9:31AM
Benzinga - Aug 17, 2021, 1:11PM
Benzinga - Aug 4, 2021, 10:21AM
Benzinga - Aug 4, 2021, 10:13AM
load more
Sector: Health Care.Industry: Biotechnology
Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-12
REV
Q1 2022Est.ActualSurprise
EPS-0.050-0.040 0.0100
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Atossa Therapeutics Questions & Answers

Q
How do I buy Atossa Therapeutics (ATOS) stock?
A

You can purchase shares of Atossa Therapeutics (NASDAQ: ATOS) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Atossa Therapeutics's (ATOS) competitors?
Q
What is the target price for Atossa Therapeutics (ATOS) stock?
A

The latest price target for Atossa Therapeutics (NASDAQ: ATOS) was reported by Ascendiant Capital on Thursday, September 17, 2020. The analyst firm set a price target for 7.00 expecting ATOS to rise to within 12 months (a possible 593.07% upside). 0 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Atossa Therapeutics (ATOS)?
A

The stock price for Atossa Therapeutics (NASDAQ: ATOS) is $1.01 last updated July 1, 2022, 8:00 PM UTC.

Q
Does Atossa Therapeutics (ATOS) pay a dividend?
A

There are no upcoming dividends for Atossa Therapeutics.

Q
When is Atossa Therapeutics (NASDAQ:ATOS) reporting earnings?
A

Atossa Therapeutics’s Q2 earnings are confirmed for Friday, August 12, 2022.

Q
Is Atossa Therapeutics (ATOS) going to split?
A

There is no upcoming split for Atossa Therapeutics.

Q
What sector and industry does Atossa Therapeutics (ATOS) operate in?
A

Atossa Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.